← Back to Search

Chemotherapy

Magnetic resonance-guided focused ultrasound for Rectal Cancer

N/A
Waitlist Available
Led By William Chu, MD, FRCPC
Research Sponsored by William Chu, MD, MSc, FRCPC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial will study if it is safe to use heat to treat cancer that has come back, using a new technology that focuses the ultrasound.

Eligible Conditions
  • Rectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acute Coryza
Secondary outcome measures
Assessment of radiologic response following treatment.
Late toxicities
Patient quality of life
+1 more

Side effects data

From 2019 Phase 2 trial • 10 Patients • NCT02000882
60%
Nausea
50%
Vomiting
50%
Fatigue
50%
Anorexia
50%
Hypokalemia
40%
Urinary tract infection
40%
Diarrhea
40%
Mucositis oral
30%
Insomnia
30%
Palmar-plantar erythrodysesthesia
30%
Rash
20%
AST increased
20%
Seizure
20%
Blurred vision
20%
Falling down
20%
Bilirubin increased
20%
ALT increased
20%
Dehyrdration
20%
Constipation
20%
Hyponatremia
20%
Headache
10%
Hypertension
10%
Facial swelling
10%
Disorder ear
10%
Epilepsy
10%
Knee Pain
10%
Rash erythematous
10%
Anemia
10%
Hypovolemia
10%
Leukopenia
10%
Neutropenia
10%
Disorder eye
10%
Eye floaters
10%
Vision abnormal
10%
Stomatitis
10%
Hand-foot syndrome
10%
Legs restless
10%
Taste alteration
10%
Allergic reaction
10%
Thrush
10%
Creatinine serum increased
10%
Amylase increased
10%
Growth accelerated
10%
Hyperglycemia
10%
Dyspnea
10%
Epistaxis
10%
Colitis
10%
Dysphagia
10%
Weakness generalized
10%
Visual disturbance
10%
Abdominal Pain
10%
Canker sore oral
10%
Cramp abdominal
10%
Dry mouth
10%
Gastritis
10%
Hemorrhoids
10%
Pancreatitis
10%
Spasm oropharyngeal
10%
Hypocalcemia
10%
Lipase increased
10%
Dizziness
10%
Edema cerebral
10%
Neuropathy
10%
Numbness
10%
Somnolence
10%
Tremor
10%
Agitation
10%
Depression
10%
Emotional lability
10%
Incontinence urinary
10%
Renal function abnormal
10%
Potassium deficiency
10%
Muscle weakness
10%
Dysgeusia
100%
80%
60%
40%
20%
0%
Study treatment Arm
BKM120 Plus Capecitabine

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRg-FUExperimental Treatment3 Interventions
Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic resonance-guided focused ultrasound
2015
N/A
~10
Standard Radiation
2015
N/A
~10
Capecitabine
FDA approved

Find a Location

Who is running the clinical trial?

William Chu, MD, MSc, FRCPCLead Sponsor
Dr. William ChuLead Sponsor
Philips Medical SystemsIndustry Sponsor
18 Previous Clinical Trials
16,508 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer
William Chu, MD, MSc, FRCPC 2015. "Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02528175.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top